Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) - Full Text View

Sponsored by:	Rigshospitalet, Denmark
Information provided by:	Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:	NCT00817284

Purpose

Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab. The 6-month progression-free survival rate is 30% and median survival duration is 9 months. The current first line therapy of GBM patients following initial surgical resection/debulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy. Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen. Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational.

The toxicity from the combined use of the two drugs prior to radiotherapy, as well as the toxicity when administered together with radiotherapy, is evaluated. This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.

Condition	Intervention	Phase
Glioblastoma Multiforme	Drug: bevacizumab and Irinotecan and radiotherapy Drug: Bevacizumab and Temozolomide and radiotherapy	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme

Resource links provided by NLM:

MedlinePlus related topics: Radiation Therapy

Drug Information available for: Temozolomide Irinotecan U 101440E Irinotecan hydrochloride Bevacizumab

U.S. FDA Resources

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:

Obsjective response rate according to McDonald criteria [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Progression-free survival [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	November 2008
Estimated Study Completion Date:	November 2010
Estimated Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
arm I: Experimental Bevacizumab + Irinotecan and concomitant radiotherapy	Drug: bevacizumab and Irinotecan and radiotherapy Bevacizumab 10 mg/kg is administered on days 1 and 15. Irinotecan: 1) Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED). 2) Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs. During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
Arm II: Experimental Bevacizumab and Temozolomide and concomitant radiotherapy	Drug: Bevacizumab and Temozolomide and radiotherapy Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy. Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy. After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

Arms

Assigned Interventions

arm I: Experimental

Bevacizumab + Irinotecan and concomitant radiotherapy

Drug: bevacizumab and Irinotecan and radiotherapy

Bevacizumab 10 mg/kg is administered on days 1 and 15.
Irinotecan:
1) Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).
2) Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.
During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

Arm II: Experimental

Bevacizumab and Temozolomide and concomitant radiotherapy

Drug: Bevacizumab and Temozolomide and radiotherapy

Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.

Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy. After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Signed informed consent
Histological verified primary glioblastoma multiforme
No prior therapy for GBM, except for primary surgical resection or biopsy
PS 0-2
Age > 18
Expected survival > 3 months
Adequate liver, renal and bone-marrow function, determined as:
- Thrombocytes > 100 x 109/liter
- Hemoglobin >6.2 mmol/liter
- Leukocytes > 3 x 109/liter
- Neutrophil granulocytes > 1.5 x 109/liter
- ASAT and/or ALAT < 3 x upper normal limit
- Bilirubin < 1.5 x upper normal limit
- Serum-creatinin < upper normal limit or glomerular filtration rate >60 ml/min (corrected for age) determined by measurement of clearance of Cr-EDTA
- APTT < upper normal limit
- INR < upper normal limit
Fertile women of childbearing age must use proper anti-conception (oral contraceptives, IUD and/or condom).

Fertile men must use condom

No sign of cerebral bleeding on cerebral MR-scanning at baseline.

Exclusion criteria:

Previous therapy of GBM, including radiotherapy and the use of biological " targeted" drug, e.g.

drugs targeted against the VEGF- or EGFR pathway

Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids
Conditions (medical, social or physical) that may compromise proper information and/or follow-up
Other concurrent or previous cancer within 5 years, except adequately treated basal or planocellular skin cancer, or cervical carcinoma in situ
Significant heart disease (according to the New York Heart Association class II or more severe), clinically significant arrhythmia or unstable angina pectoris/acute myocardial infarction within last 6 months
Clinical significant peripheral arterial disease
Known or suspected disorders of coagulation or concurrent therapy with ASA, NSAID or clopidogrel
Major surgery, open biopsy or greater trauma, or expectations thereof, within 28 days prior to start of therapy
Minor surgery or needle biopsy, or expectations thereof, within 7 days prior to start of therapy
Known or suspected abdominal fistulas, gastrointestinal perforations or intra-abdominal abscesses within 6 months prior to start of therapy
Chronic inflammatory intestinal disease and/or intestinal obstruction
Known or active HIV or Hepatitis B/C infection
Concurrent ongoing significant infection or diabetes mellitus not adequately controlled medically
Clinically significant non-healing ulcers
Active ventricular or duodenal ulcers within 6 months prior to start of therapy
Recent bone-fracture (<3 months)
Pregnancy or lactation
Need for systemic anticoagulant therapy at time of start of therapy
Blood pressure > 150/100 mmHg (patients are allowed to receive proper antihypertensive medication)
Proteinuria ≥ 1 gram/day
Known allergy toward irinotecan (or related substance) or vehicle
Known allergy toward temozolomide (or related substance) or vehicle
Known allergy toward bevacizumab (or related substance) or vehicle

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00817284

Contacts

Contact: Ulrik Lassen, MD, PH.D	+45 35453545
Contact: Kenneth Hofland, MD, PH.D	+45 35453545

Locations

Denmark
Rigshospitalet	Recruiting
Copenhagen, Denmark
Principal Investigator: Ulrik Lassen, MD, PH.D
Århus Hospital	Not yet recruiting
Århus, Denmark
Principal Investigator: Henrik Schultz, MD
Odense Hospital	Not yet recruiting
Odense, Denmark
Principal Investigator: Steinbjørn Hansen, MD. PH.D

Sponsors and Collaborators

Rigshospitalet, Denmark

More Information

No publications provided

Responsible Party:	Rigshospitalet ( Ulrik Lassen )
Study ID Numbers:	BIBT-01
Study First Received:	December 8, 2008
Last Updated:	January 5, 2009
ClinicalTrials.gov Identifier:	NCT00817284 History of Changes
Health Authority:	Denmark: Danish Medicines Agency

Keywords provided by Rigshospitalet, Denmark:

Newly diagnosed patients with glioblastoma multiforme.
Performance status 0-2.

Study placed in the following topic categories:

Glioblastoma
Astrocytoma
Irinotecan
Bevacizumab
Angiogenesis Inhibitors
Temozolomide
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal

Neuroepithelioma
Glioma
Glioblastoma Multiforme
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Alkylating Agents
Anticonvulsants
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Glioblastoma
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Irinotecan
Neoplasms, Nerve Tissue
Physiological Effects of Drugs
Bevacizumab
Neoplasms, Germ Cell and Embryonal
Therapeutic Uses
Growth Inhibitors
Glioma
Angiogenesis Modulating Agents
Alkylating Agents

Neoplasms by Histologic Type
Astrocytoma
Growth Substances
Enzyme Inhibitors
Temozolomide
Angiogenesis Inhibitors
Pharmacologic Actions
Neuroectodermal Tumors
Neoplasms
Antineoplastic Agents, Alkylating
Neoplasms, Neuroepithelial
Antineoplastic Agents, Phytogenic
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on September 02, 2009